Necrostatin-1 (Nec-1) was first developed as a receptor-interacting protein kinase 1 (RIPK1) inhibitor and has been used to treat other acute central nervous system disorders that feature necroptosis as a mode of cell death1. The gene discussed is RIPK1; the disease is central nervous system disorder.